Answers are grounded in this paper and cite their sources.
Policy analysis reveals factors behind generic drug shortages, suggesting strategies to streamline FDA approval processes.
Problem: Generic drugs account for approximately 90 percent of U.S. prescriptions but experience the highest rates of supply disruption among all drug categories. Drug shortages reached a 23-year high in the first quarter of 2024, with 323 active shortages reported by the American Society of Health-System Pharmacists (ASHP, 2024). The FDA, GAO, and HHS have consistently identified regulatory submission deficiencies as a recurring contributor to delays in generic drug market entry. Approach: This study presents a secondary-source policy analysis drawing on FDA regulatory review data, GAO audit findings, HHS supply chain reports, and the author’s operational experience in international CTD/eCTD submissions to examine where and why FDA ANDA approval processes break down. Findings: The most frequent bottlenecks arise from preventable submission quality deficiencies, particularly in CTD Module 3 (CMC), data integrity issues identified during pre-approval inspections, inadequate pharmacovigilance planning, and poor cross-functional coordination during dossier preparation. Evidence from COVID-19 emergency authorizations suggests that regulatory timelines can be compressed when teams implement parallel preparation processes and engage regulators earlier in the submission lifecycle. Contribution: The paper proposes four evidence-based, FDA-aligned operational strategies to improve ANDA submission quality and reduce approval timelines, alongside policy recommendations for FDA, industry, and regulatory workforce development.
No takes yet. Share an insight, caveat, or question.
Sumiya Mushtaq (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: